The US tariff regime on pharmaceuticals is built around a single condition: manufacture in the US or pay. Drugmakers that have announced plants stateside got tariff relief; everyone else faces the threat of rates running into the tens of percent, and in the extreme case the hundreds. The EU negotiated a ceiling of 15 percent, but that ceiling is part of a broader trade deal that Washington is now publicly pressing Brussels to honor. Pharmaceuticals are the single largest line item in European exports to the States, which makes them the natural hostage in this standoff.
The problem is that the announced investments, which already add up to several hundred billion dollars, solve nothing this decade. A new biologics plant is four to six years from groundbreaking to first commercial batch, and at the end of that road there is still an FDA pre-approval inspection. Even simply moving an existing product into an already operating, approved facility requires a supplement to the registration dossier, a technology transfer, validation runs and comparability studies, typically 18 to 36 months. The tariff, by contrast, bites immediately. Between these two clocks a multi-year gap opens up, and that gap is what this thesis is really about.